In the NJDT cohort, the promoter methylation CT values of both SHOX2 and RASSF1A in tumor samples at Stage I and II were significantly lower than those in normal samples (Wilcoxon test, P < 0.05) (Figure 4B). The gene discussed is RASSF1; the disease is neoplasm.